Publications

Cancers

A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer.

16-01-2021

Key

Nature

The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy.

04-12-2024

Cancer discovery

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.

02-12-2024

Breast (Edinburgh, Scotland)

Nodal involvement in patients with small, clinically node-negative HER2-positive breast cancer after staging with FDG-PET/CT and neoadjuvant systemic therapy.

01-12-2024

Nature communications

An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.

07-11-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

01-11-2024

Breast cancer research and treatment

Cardiovascular disease risk after breast cancer treatment in patients with a BRCA1/2 pathogenic variant.

31-10-2024

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Academic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.

20-10-2024

Clinical cancer research : an official journal of the American Association for Cancer Research

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.

03-09-2024

iScience

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.

16-08-2024

JAMA oncology

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

01-08-2024

bioRxiv : the preprint server for biology

Automated classification of cellular expression in multiplexed imaging data with Nimbus.

03-06-2024

Breast (Edinburgh, Scotland)

Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.

01-06-2024

Annals of oncology : official journal of the European Society for Medical Oncology

Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: does it help tailor adjuvant treatment?

01-05-2024

JAMA

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

02-04-2024

ESMO open

Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.

01-03-2024

Cancers

The Additional Value of Somatostatin Receptor Positron Emission Computed Tomography ([⁶⁸Ga]Ga-DOTATOC PET/CT) Compared with Magnetic Resonance Imaging of the Head and Neck Region in Paraganglioma Patients: A Pilot Study.

28-02-2024

BMC medicine

Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.

09-01-2024

Immunity

Chi3l1: New kid on the T cell blockade.

12-12-2023

Seminars in oncology

Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects.

01-12-2023

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

A qualitative study on the healthcare experiences of adolescents and young adults (AYA) with an uncertain or poor cancer prognosis.

27-11-2023

Journal for immunotherapy of cancer

Quantifying the impact of immunotherapy on RNA dynamics in cancer.

01-11-2023

Breast cancer research : BCR

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.

04-10-2023

Breast (Edinburgh, Scotland)

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

01-08-2023

Clinical cancer research : an official journal of the American Association for Cancer Research

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer.

05-07-2023

The oncologist

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.

05-07-2023

Current treatment options in oncology

Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.

01-06-2023

NPJ breast cancer

Immune landscape of breast tumors with low and intermediate estrogen receptor expression.

13-05-2023

Oncoimmunology

Neoadjuvant immune checkpoint blockade triggers persistent and systemic T_reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors.

24-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].

01-03-2023

International journal of molecular sciences

Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.

03-02-2023

Cancer cell

IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer.

09-01-2023

Nature communications

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

21-11-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.

01-11-2022

Annals of oncology : official journal of the European Society for Medical Oncology

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.

01-08-2022

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.

20-07-2022

Nature communications

Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer.

27-06-2022

Expert opinion on investigational drugs

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

01-06-2022

British journal of cancer

Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.

01-06-2022

NPJ breast cancer

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.

28-04-2022

Nature cancer

LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer.

01-03-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.

01-03-2022

Virchows Archiv : an international journal of pathology

Incorporation of TILs in daily breast cancer care: how much evidence can we bear?

01-01-2022

Breast care (Basel, Switzerland)

Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).

01-12-2021

NPJ breast cancer

The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.

01-12-2021

Science translational medicine

Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers.

27-10-2021

Cancers

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

29-09-2021

Nature communications

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

27-09-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

01-09-2021